Food and Drug Regulations (C.R.C., c. 870)

C.03.306. A research ethics board has all of the following characteristics:

• (a) its principal mandate is to approve the initiation of and to periodically review biomedical research that involves human subjects in order to protect their rights, safety and well-being;

• (b) it has at least five members, a majority of whom are Canadian citizens or permanent residents under the Immigration and Refugee Protection Act, is composed of both men and women and includes at least the following:

  • (i) two members whose primary experience and expertise are in a scientific discipline, who have broad experience in the methods and areas of research to be approved and one of whom is from a medical discipline,

  • (ii) one member knowledgeable in ethics,

  • (iii) one member knowledgeable in Canadian laws relevant to the research to be approved,

  • (iv) one member whose primary experience and expertise are in a non-scientific discipline, and

  • (v) one member who is from the community or is a representative of an organization interested in the areas of research to be approved and who is not affiliated with the sponsor or with the study site; and

• (c) it has no affiliations with the sponsor that could compromise its ability to fulfil its principal mandate, or that could be perceived to do so.

• C.03.307. (1) The sponsor shall submit to the Minister an application for authorization to sell or import a study drug that contains the information set out in subsection (2) as well as sufficient information to demonstrate that all of the following criteria are met:

  • (a) the use of the study drug will not endanger the health of any study subject or other person;

  • (b) the study is not contrary to the best interests of the study subjects; and

  • (c) the objectives of the study can reasonably be achieved.

• (2) The application shall contain all of the following information:

  • (a) the title of the study and the protocol code or identification;

  • (b) the purposes and a concise description of the study;

  • (c) the number of study subjects;

  • (d) the brand name, if any, of the study drug;

  • (e) the chemical or generic name of the active ingredients in the study drug;

  • (f) a qualitative list of the non-active ingredients of the study drug;

  • (g) the maximum mass of the study drug to be administered to each study subject;

  • (h) the radioactive dose range of the study drug, expressed in MBq or mCi;

  • (i) the effective dose or effective dose equivalent of the study drug, expressed in mSv/MBq or rem/mCi;

  • (j) the sponsor’s name and civic address, its postal address if different, and its telephone number, fax number and email address;

  • (k) the manufacturer’s name and civic address, its postal address if different, and its telephone number, fax number and email address;

  • (l) in the case of an application for importation, the name and civic address, the postal address if different, and the telephone number, fax number and email address of the manufacturer’s representative in Canada who is responsible for the sale of the study drug;

  • (m) the name and civic address of each study site;

  • (n) for each study site, the name, civic address, telephone number, fax number and email address of the qualified investigator;

  • (o) the proposed starting date for the study at each study site, if known;

  • (p) for each study site, the name, civic address, telephone number, fax number and email address of the research ethics board;

  • (q) a statement, dated and signed by the research ethics board for each study site, that certifies that it has reviewed and approved the study, the protocol and the statement of the risks and anticipated benefits arising to the health of study subjects as a result of participating in the study that is set out in the informed consent form;

  • (r) a list of any previous applications for an authorization to sell or import a drug for a study related to the current study; and

  • (s) a statement, dated and signed by the sponsor’s senior medical or scientific officer in Canada and senior executive officer, that certifies both of the following:

    • (i) the study will be conducted in accordance with these Regulations, and

    • (ii) all of the information contained or referred to in the application is complete and accurate and is not false or misleading.